Biosimilars Market Size to Grow at a CAGR of 25.9% in the Forecast Period of 2023-2028
IMARC Group, a leading market research company, has recently releases report
titled “Biosimilar Market: Global Industry Trends, Size, Share, Growth,
Opportunity and Forecast 2023-2028.” The study provides a detailed
analysis of the industry, including the global Biosimilar Market share, size,
trends, and growth forecasts. The report also includes competitor and regional
analysis and highlights the latest advancements in the market.
Report Highlights
How big is the Biosimilar market?
|
Report Attributes |
Details |
|
Market Size in 2022 |
US$ 16.8 Billion |
|
Market Forecast in 2028 |
US$ 77.1 Billion |
|
Growth rate (2023 to 2028) |
CAGR of 25.9% |
|
Base Year of the Analysis |
2022 |
|
Forecast Period |
2023-2028 |
What are Biosimilars services?
Biosimilars are biotherapeutic products that are particularly identical to a
reference biologic drug. They are produced using living organisms and cells
that have complex molecular structures. To be labeled as a biosimilar, a
biological drug must be proved similar in terms of efficacy, safety, and
quality. Biosimilars are comparatively more expensive than generic drugs as
their production process is complex and requires considerable investments in
research and development (R&D) activities.
Request for a Free PDF Sample of this Report: https://www.imarcgroup.com/biosimilar-market/requestsample
What are the growth prospects and trends in the Biosimilars
industry?
The surging prevalence of chronic diseases, such as cancer and autoimmune diseases, especially among the geriatric population, represents one of the key factors significantly contributing to the market growth. Additionally, the growing instances of patent expiration and loss of protection in several biologic drugs are creating a positive outlook for the market. The manufacturers have to resort to approval from the regulatory authorities once their patent expires to start the production of biosimilars. Moreover, biosimilars do not require extensive marketing, as the efficacy and safety profile of their branded counterparts has already been established, which, in turn, is working in favor of the market growth. Besides this, the high costs related to innovator biologics, especially monoclonal antibodies (mAbs), have compelled governments to undertake initiatives encouraging the usage of biosimilars over branded biologics due to their cost-effectiveness, which is accelerating the market growth.
Who are the key players operating in the Biosimilars industry?
The report covers the major market players including:
- Novartis
- Pfizer
- Teva
- Celltrion
- Merck
& Co
- Samsung
Bioepis
- Eli
Lilly
- Biocon
- Reddy's
Laboratories
- Amgen
- Boehringer
Ingelheim
What is included in market segmentation?
The report has segmented the market into the following categories:
Molecule insights:
- Infliximab
- Insulin
Glargine
- Epoetin
Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin
Alfa
Indication Insights:
- Auto-Immune
Diseases
- Blood
Disorder
- Diabetes
- Oncology
- Growth
Deficiency
- Female
Infertility
Manufacturing Insights:
- In-house
Manufacturing
- Contract
Manufacturing
Regional Insights:
- United
States
- Germany
- France
- Italy
- Spain
- United
Kingdom
- Japan
- India
- South
Korea
- Others
About Us
IMARC Group is a leading market research company that offers management strategy
and market research worldwide. We partner with clients in all sectors and
regions to identify their highest-value opportunities, address their most
critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific,
economic and technological developments for business leaders in pharmaceutical,
industrial, and high technology organizations. Market forecasts and industry
analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage,
travel and tourism, nanotechnology and novel processing methods are at the top
of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
